id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-305119-y3a1qyi9	Price, Kyla N.	COVID-19 and immunomodulator/immunosuppressant use in dermatology	2020-03-26		.txt	text/plain	818	61	38	The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the current coronavirus disease 2019 (COVID-19) outbreak. We agree that this time has been particularly concerning for patients taking immunomodulators/immunosuppressants who are unsure of their risk for severe disease. In response to the previous commentary, the goal of this letter is to expand and provide the latest information about COVID-19 along with considerations for addressing patient concerns surrounding dermatology-related immunomodulator/immunosuppressant use. Theoretical data from previous coronavirus outbreaks has suggested a strong role for type I interferon, B-cellereleased antibodies, tumor necrosis factor-, and other cytokines in the viral immune response (Fig 1) . Immunosuppressants decrease cytokines that recruit and differentiate immune cells needed to clear the infection. Currently, there are no data describing the benefits or risks of stopping immunomodulators/ immunosuppressants during the COVID-19 outbreak.	./cache/cord-305119-y3a1qyi9.txt	./txt/cord-305119-y3a1qyi9.txt